Rock Springs Capital Management LP Cut Its Prothena Plc (Call) (PRTA) Stake; Xbiotech (XBIT) Shorts Decreased By 4.21%

Prothena Corporation plc (NASDAQ:PRTA) Logo

Xbiotech Inc (NASDAQ:XBIT) had a decrease of 4.21% in short interest. XBIT’s SI was 2.53M shares in November as released by FINRA. Its down 4.21% from 2.64M shares previously. With 36,500 avg volume, 69 days are for Xbiotech Inc (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Inc’s float is 12.85%. The stock increased 2.38% or $0.1 during the last trading session, reaching $4.3. About 8,359 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 36.41% since November 22, 2017 and is downtrending. It has underperformed by 52.03% the S&P500. Some Historical XBIT News: 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC

Rock Springs Capital Management Lp decreased Prothena Corp Plc (Call) (PRTA) stake by 37.04% reported in 2018Q2 SEC filing. Rock Springs Capital Management Lp sold 50,000 shares as Prothena Corp Plc (Call) (PRTA)’s stock declined 3.28%. The Rock Springs Capital Management Lp holds 85,000 shares with $1.24M value, down from 135,000 last quarter. Prothena Corp Plc (Call) now has $475.57 million valuation. The stock increased 2.84% or $0.33 during the last trading session, reaching $11.93. About 196,562 shares traded. Prothena Corporation plc (NASDAQ:PRTA) has declined 77.78% since November 22, 2017 and is downtrending. It has underperformed by 93.40% the S&P500. Some Historical PRTA News: 24/05/2018 – Prothena to Concentrate Resources Around Neuroscience Research, Discovery and Early Development Expertise; 24/05/2018 – PROTHENA – REORGANIZATION INCLUDES DISCOVERY-STAGE PIPELINE, 3 PROGRAMS BEING ADVANCED UNDER COLLABORATION WITH CELGENE; 24/05/2018 – PROTHENA : SEES TO CUT ABOUT 63 POSITIONS; 24/05/2018 – PROTHENA CORPORATION PLC – EXPECTS 2018 NET CASH BURN FROM OPERATING & INVESTING ACTIVITIES TO BE $40 TO $50 MLN; 20/03/2018 – Celgene goes all-out on neurodegeneration and Alzheimer’s, triggering blockbuster deal with $150M in cash for Prothena $CELG $PRTA; 25/05/2018 – The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Prothena Corporation (PRTA); 25/05/2018 – IGNORE: PROTHENA CORP. REORGANIZATION PLAN ANNOUNCED YESTERDAY; 24/05/2018 – PROTHENA CORPORATION PLC – AS A RESULT OF DISCONTINUATION OF NEOD001 DEVELOPMENT PROGRAM, WILL REDUCE WORKFORCE BY ABOUT 57 PERCENT; 17/05/2018 – Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Prothena Corporation plc And Certain Of Its Current And Former Senior Executives; 20/03/2018 – Prothena, Celgene Collaboration Focuses on Preclinical Programs Targeting Proteins Implicated in Neurodegenerative Diseases

Rock Springs Capital Management Lp increased Aeglea Biotherapeutics Inc stake by 125,911 shares to 650,000 valued at $6.88 million in 2018Q2. It also upped Nuvasive Inc (NASDAQ:NUVA) stake by 67,500 shares and now owns 372,500 shares. Momenta Pharmaceuticals Inc (NASDAQ:MNTA) was raised too.

Investors sentiment decreased to 0.86 in Q2 2018. Its down 0.03, from 0.89 in 2018Q1. It dived, as 31 investors sold PRTA shares while 28 reduced holdings. 20 funds opened positions while 31 raised stakes. 29.12 million shares or 2.41% less from 29.85 million shares in 2018Q1 were reported. Quantbot Technologies Limited Partnership reported 7,798 shares. Aqr Capital Mgmt Llc accumulated 0% or 16,630 shares. Moreover, Cornerstone Advsr has 0% invested in Prothena Corporation plc (NASDAQ:PRTA). Blackrock Inc stated it has 0% in Prothena Corporation plc (NASDAQ:PRTA). The Pennsylvania-based Vanguard Grp Inc has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Bogle Inv Mngmt LP De has 0.02% invested in Prothena Corporation plc (NASDAQ:PRTA). Carroll Financial Inc, a North Carolina-based fund reported 1 shares. Clearbridge Invs Ltd Liability Com holds 0% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA) for 24 shares. State Street Corporation accumulated 3.42M shares. Piedmont Investment Ltd Liability Com holds 698 shares or 0% of its portfolio. Daiwa Inc reported 212 shares stake. California State Teachers Retirement Systems accumulated 0% or 61,491 shares. 33,443 were accumulated by Invesco Limited. Envestnet Asset Mgmt reported 53 shares. Focused Wealth Management reported 0.05% stake.

Another recent and important Prothena Corporation plc (NASDAQ:PRTA) news was published by which published an article titled: “Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update” on November 06, 2018.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $154.03 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *